Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Opening of new Yourgene Health Canada Inc. facilities
Supporting future growth for Ranger® Technology
Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Canada Inc. will launch its new expanded facilities at 702 – 1515 Broadway Street, Port Coquitlam, Vancouver, BC V3C 6M2, today from 12:30 (PST).
The opening will be led by Mayor Brad West, Mayor of Port Coquitlam and will include a tour of the facilities followed by speeches and a lunch for those in attendance. The new facilities are four times the square footage of the former location and will be well suited for the expected growth in the Company’s instrument manufacturing and consumable shipping requirements. Yourgene took over the facilities in December 2021 following an increased headcount by 120% over 2021 and the Company is currently involved in a hiring plan that will add another six team members by April 2022.
Coastal Genomics Inc. has been renamed Yourgene Health Canada Inc. following the acquisition in August 2020, to further integrate Coastal Genomics into the larger Yourgene Health group of companies.
Lyn Rees, Chief Executive Officer, commented: ‘We are delighted to be in our new facilities, which will truly support the scale up of manufacturing of our Ranger® Technology platforms, reagents and consumables to support our growing global customer base.”
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
|Singer Capital Markets (Joint Corporate Broker)|
Aubrey Powell / Tom Salvesen / George Tzimas
|Tel: +44 (0)20 7496 3000|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
Tel: +44 (0)20 7710 7600
Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Alice Woodings
Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 Mob: 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.